HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more

Abstract : After many years of research, recent advances have shed new light on the role of the immune system in advanced-stage cancer. Various types of immune cells may be useful for therapeutic purposes, along with chemical molecules and engineered monoclonal antibodies. The immune effectors suitable for manipulation for adoptive transfer or drug targeting in vivo include natural killer (NK) cells. These cells are of particular interest because they are tightly regulated by an array of inhibitory and activating receptors, enabling them to kill tumor cells while sparing normal cells. New therapeutic antibodies blocking the interactions of inhibitory receptors (immune checkpoint inhibitors, ICI) with their ligands have been developed and can potentiate NK cell functions in vivo.
Document type :
Journal articles
Complete list of metadata

Contributor : Carine Dou Goarin Connect in order to contact the contributor
Submitted on : Thursday, April 12, 2018 - 12:12:59 PM
Last modification on : Wednesday, November 3, 2021 - 9:38:22 AM




Laura Chiossone, Margaux Vienne, Yann M. Kerdiles, Eric Vivier. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. Seminars in Immunology, Elsevier, 2017, 31 (SI), pp.55-63. ⟨10.1016/j.smim.2017.08.003⟩. ⟨hal-01764667⟩



Record views